Psilocybin-assisted Therapy for End-of-Life Distress [ONLINE]
April 27 @ 5:00 pm - 6:30 pm
by Mind Medicine Australia
Psilocybin has been being researched by various institutions, including NYU and John Hopkins, for its potential therapeutic benefit to combat end-of-life anxiety due to terminal illness and cancer. The study results are fascinating:
At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60–80% of participants continued with clinically significant reductions in depression or anxiety), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression.
In this presentation, Gabby Agin-Liebes, a co-author of the psilocybin study quoted above and a PhD student studying clinical psychology, we explore:
- Formation of the NYU study
- Gabby’s role in the study
- How volunteers were selected
- Inclusion and admission criteria
- Study results
- Can psilocybin help those who are facing death?
- Current research that Gabby is part of and co-leading
- How to get involved in the psychedelic field
- Dreams and visions for the future of psychedelics and psychedelic research
Following the presentation, there will be a Q & A panel with Dr Gabby Agin-Liebes and Tania de Jong AM. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.